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doi:10.1016/j.pedneo.2012.04.004Objective: To evaluate the effects on neonatal outcomes between very-low-birth-weight
(VLBW) preterm newborns with and without maternal use of antenatal corticosteroids (ACS).
Methods: We retrospectively reviewed medical records of VLBW premature infants who were
admitted to Kaohsiung Medical University Hospital between 1999 and 2008. A total of 256
infants were enrolled in this study. A total of 174 neonates did not receive any ACS, and 82
neonates received ACS. A total of 37 neonates received one dose of ACS, and 45 neonates
received more than one dose of ACS, referred to as “multiple-dose ACS.” In addition, these
82 infants were divided to betamethasone group (nZ 8) and dexamethasone group (nZ 50)
with 24 infants excluded because of inadequate information.
Results: Neonates with multiple-dose ACS had lower incidence of surfactant use and lower rate
of intubation than neonates without ACS. There were no differences in the occurrences of
intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, sepsis,
and chronic lung disease with one-dose vs. multiple-dose ACS and in the betamethasone group
vs. the dexamethasone group.u.tw (H.-L. Chen).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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tube insertion at birth in VLBW premature infants.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The morbidity and mortality rates of premature infants are
much higher than those of full-term babies. Lung matura-
tion is one of the main problems. Premature infants have
higher incidence of respiratory distress syndrome (RDS),
which is one of the main causes of early neonatal mortality.
Corticosteroids can stimulate the maturation of alveolar
type 2 cells to produce surfactant and elicit architectural
maturation of the fetal lung.1 Therefore, antenatal corti-
costeroid (ACS) can reduce the incidence of RDS, perinatal
and neonatal death, and severe morbidity in premature
infants below 32 weeks’ gestation.2
The National Institute of Health3 recommended that for
mothers with gestational age between 24 and 34 weeks, use
of ACS may improve the outcome of preterm infants, and,
in particular, reduce the incidence and severity of RDS.
Recommendation of ACS treatment consists of two doses of
12 mg of betamethasone given intramuscularly 24 hours
apart or four doses of 6 mg of dexamethasone given intra-
muscularly 12 hours apart.
Several studies regarding repeated courses or weekly
courses of ACS for preterm infants to enhance their lung
maturation were reported. One Cochrane systematic
review4 in 2007 suggested that weekly courses of ACSwere
associated with reduced occurrence and severity ofneona-
tal lung disease, and of serious infant morbidity. Subse-
quently, some studies showed multiple courses of ACS do
not improve preterm-birth outcomes,5,6 and are associated
with a decreased weight, length, and head circumference
at birth,5 and would increase the risk of leukomalacia and
2-year infant neurodevelopmental abnormalities.7
This study was a clinical retrospective study to analyze
the beneficial effects and possible adverse effects on
neonatal outcomes in premature infants with and without
maternal use of ACS.
2. Participants and Methods
2.1. Participants
This study was a retrospective study including all the
neonates with very low birth body weight (VLBW; birth body
weight less than 1500 gm) who were admitted to the
neonatal intensive care unit of Kaohsiung Medical Univer-
sity Hospital between 1999 and 2008. The babies with major
structural anomalies, chromosomal abnormalities, and
steroid use for other indications were excluded. Patients
without information regarding prenatal ACS were also
excluded.
Infants were divided into no-ACS group, one-dose ACS
group, and multiple-dose ACS group to evaluate thedifferent outcomes between these three groups. The no-
ACS group included babies who did not receive ACS. The
one-dose ACS group included babies who received one dose
of antenatal betamethasone or dexamethasone. The
multiple-dose ACS group included infants who received
more than one dose of betamethasone or dexamethasone.
We further separated infants into a no-ACS group, beta-
methasone group, and dexamethasone group to evaluate
the different outcomes between these three groups.
These groups were compared for basic characteristics
such as gestational age, birth weight, small for gestational
age (SGA), and male sex. The data of maternal age,
gravida, the incidence of twins, gestational diabetes mel-
litus (GDM), toxemia, the incidence of caesarean section,
and emergency delivery were also evaluated between these
groups.
The neonatal outcomes including survival rate, Apgar
scores at 1 minute and 5 minutes, the need for intubation,
the need for surfactant treatment, and the incidence and
duration of mechanical ventilation were analyzed. In
addition, the duration of oxygen dependence, the inci-
dence and treatment rate of patent ductus arteriosus
(PDA), intraventricular hemorrhage (IVH), necrotizing
enterocolitis (NEC), early- and late-onset neonatal sepsis,
retinopathy of prematurity (ROP), and chronic lung disease
(CLD) were also reviewed. Neurologic outcomes were
measured by the Bayley Scales of Infant Development II at
the corrected ages of 6, 12, 18, and 24 months.
PDA was diagnosed by a pediatric cardiologist under
echocardiography and then followed up until the PDA had
closed. All neonates had cerebral ultrasound scans for
detection of IVH by a pediatric neurologist. NEC was clini-
cally and radiographically diagnosed by using modified
Bell’s criteria.8 Neonatal sepsis was defined by clinical
manifestation with positive blood cultures. ROP survey was
performed by ophthalmologists. CLD was defined as a need
for supplemental oxygen at the postconceptional age (PCA)
of 36 weeks.
2.2. Statistical analysis
Continuous data are expressed asmean standard deviation
(SD). In the comparison of ACS groups, analysis of variance
(ANOVA)/t-test for numerical measurement and Chi-square
test for categorical measurement. Tukey’s pairwise
comparison was used if the p value of ANOVAwas significant.
The odds ratio of multiple-dose ACS group compared with
one-dose ACS group for developing outcomes was estimated
by a logistic regression model with adjusting of birth body
weight and gestational age at delivery. Statistical analyses
were conducted by software JMP 8.0 (SAS Institutes Inc.,
Cary, NC, USA), and p values less than 0.05 were considered
statistically significant in all testing.
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A total of 256 infants were enrolled in the study. A total of
174 neonates (68%) did not receive any ACS, and 82
neonates (32%) received one or more doses of ACS. Thirty-
seven infants (14%) received one dose of ACS, and 45
infants (18%) received multiple doses of ACS before
delivery. In these 82 neonates who received any doses of
ACS, there were eightinfants who received ACS as beta-
methasone, 50 infants received dexamethasone, and 24
infants about whom there was not adequate information
regarding ACS type.
The basic characteristics of the study population are
shown in Table 1. Gestational age at delivery, birth weight,
the percentage of SGA, and male sex were not significantly
different between the no-ACS, one-dose ACS, and multiple-
dose ACS group. There were also no differences in maternal
age, gravida, twins, and maternal GDM, toxemia, rate of
caesarean section, or emergent delivery.
The survival rate of the one-dose ACS group (91.9%) and
multiple-dose ACS (91.1%) was higher than that of the no-
ACS group (83.3%), although there was no significant
difference (pZ 0.218; Table 2). The one-dose ACS group
and the multiple-dose ACS group reduced the need for
surfactant and intubation. In addition, the occurrence of
surfactant and intubation were significantly lower in the
multiple-dose ACS group than in the no-ACS group
(pZ 0.007 and 0.043, respectively). There was no differ-
ence in the incidence of PDA, IVH, NEC, ROP, sepsis,
mechanical ventilation duration, or duration of oxygen
dependence between these three groups. The long-term
neurologic outcomes evaluated by Bayley Scales of Infant
Development II showed no significant different among the
three groups (data not shown). The influence of one-dose
ACS and multiple-dose ACS on neonatal outcome esti-
mated by a logistic regression adjusted for birth weight and
gestational age at delivery was demonstrated in Table 3.
There were no significantly differences on the rate of
surfactant and intubation between one-dose ACS and
multiple-dose ACS.
Table 4 reveals the neonatal outcomes between the
no-ACS, betamethasone, and dexamethasone groups.Table 1 Patient characteristics of study infants.
Basic No-ACS
(nZ 174)
Gestational age
(weeks, mean SD)
29.0 3.1
Birth weight (g, mean SD) 1147 262
Male (n, %) 98 (56.3%)
Maternal age (yr, mean SD) 29.4 5.7
Gravida (mean SD, range) 2 2 (1e17)
Twin (n, %) 41 (23.7%)
GDM (n, %) 3 (1.8%)
Toxemia (n, %) 30 (17.8%)
Caesarean section (n, %) 95 (56.6%)
Emergency delivery (n, %) 53 (31.6%)
*p value: analysis of variance/t-test for numerical measurement and
ACSZ antenatal corticosteroids; GDMZ gestational diabetes mellitusThe dexamethasone group (36.73%) had a lower rate of
surfactant use than that of the no-ACS group (66.28%) and
betamethasone group (71.43%) (pZ 0.001). In addition, the
dexamethasone group (54%) had lower rate of intubation
than no-ACS group (74.14%) and betamethasone group (75%)
(pZ 0.022). The rates of surfactant use between the
betamethasone and the dexamethasone groups were not
significantly different (pZ 0.081), and the need for intu-
bation between the betamethasone and the dexametha-
sone groups was not significantly different (pZ 0.265).
There were no significant differences in the rate of survival,
IVH, NEC, ROP, or sepsis among these three groups. The
incidence of PDA was significantly lower in the betame-
thasone group, though the rate of PDA needing operation/
indomethacin intervention was not significantly different.4. Discussion
This study mainly investigated the effects of ACS on the
outcomes of VLBW premature infants. We also compared
the neonatal outcomes of one-dose vs. multiple-dose ACS,
and betamethasone vs. dexamethasone, in VLBW preterm
infants. Our major results included (a) ACS diminished the
need of intubation and the need for surfactant use in VLBW
premature infants, and (b) preterm infants with one-dose
ACS had outcomes comparable to those who with
multiple-dose ACS.
It is well known that preterm infants have higher inci-
dence of immature lung development, higher morbidity and
mortality, and more neurologic sequel.9 ACS can accelerate
fetal lung maturation and decrease the risk of premature
infants developing RDS.10,11 Preterm babies who have been
exposed repeated courses of ACS had lower incidence of
RDS than those who have been exposed one course of ACS in
some studies,4,12 but other studies5,6 showed there was no
significant difference between repeated courses and one
course of ACS treatment. One-dose antenatal betametha-
sone had lower rate of surfactant treatment than no ACS in
the premature infants,13 but there are no reports on the
neonatal outcomes of one-dose vs. multiple-dose ACS and
antenatal betamethasone vs. antenatal dexamethasone inOne-dose
ACS (nZ 37)
Multiple-dose
ACS (nZ 45)
p value*
29.1 2.6 29.4 2.2 0.641
1199 224 1185 196 0.388
20 (54.1%) 23 (51.1%) 0.816
30.0 4.7 30.8 4.8 0.320
2 2 (1e11) 2 1 (1e6) 0.456
6 (16.2%) 10 (22.2%) 0.614
1 (2.9%) 1 (2.3%) 0.911
10 (28.6%) 4 (9.1%) 0.080
19 (59.4%) 27 (64.3%) 0.658
11 (34.4%) 12 (29.3%) 0.900
chi-square test for categorical measurement.
; SDZ standard deviation.
Table 2 Neonatal outcomes of study population who exposed different dose of antenatal corticosteroids.
Basic No-ACS
(nZ 174)
One-dose
ACS (nZ 37)
Multiple-dose
ACS (nZ 45)
p value*
Survival (n, %) 145 (83.3%) 34 (91.9%) 41 (91.1%) 0.218
Apgar score < 7 at 1 min (n, %) 139 (79.9%) 27 (73.0%) 32 (71.1%) 0.363
Apgar score < 7 at 5 min (n, %) 62 (35.6%) 8 (21.6%) 13 (28.9%) 0.220
Need for surfactant (n, %) 114 (66.3%) 18 (48.7%) 18 (42.9%) 0.007
Need for intubation (n, %) 129 (74.1%) 24 (64.9%) 25 (55.6%) 0.043
Duration oxygen dependence (d, mean SD) 42 41 50 52 33 34 0.207
Duration of mechanical ventilator (d, mean SD) 12 24 12 23 8 36 0.693
PDA (n, %) 98 (56.3%) 22 (59.5%) 23 (51.1%) 0.736
PDA with need of indomethacin/ligation (n, %) 71 (72.5%) 11 (50.0%) 14 (60.9%) 0.282
IVH (n, %) 37 (22.0%) 8 (22.2%) 12 (27.9%) 0.713
IVH S Grade III (n, %) 11 (6.43%) 6 (16.7%) 2 (4.65%) 0.085
ROP any stage (n, %) 38 (30.7%) 11 (35.5%) 8 (22.9%) 0.521
ROP SStage III (n, %) 17 (13.7%) 2 (6.5%) 1 (2.9%) 0.132
Sepsis < 48 hr after birth (n, %) 52 (30.0%) 11 (29.7%) 11 (24.4%) 0.538
Sepsis during hospitalization (n, %) 58 (33.3%) 15 (40.5%) 13 (28.9%) 0.770
Necrotizing enterocolitis (n, %) 8 (4.6%) 2 (5.6%) 4 (8.9%) 0.533
Chronic lung disease (N1, N2, %) 59, 151, 39.1 14,36,38.9 9, 42, 21.4 0.100
*p value: analysis of variance/t-test for numerical measurement and chi-square test for categorical measurement.
%Z N1/N2PDA patent ductus arteriosus; ACSZ antenatal corticosteroids; IVHZ intraventricular hemorrhage; N1Z infants who used O2
at 36 wks after conception; N2Z infants who survived> 36 wks; ROPZ retinopathy of prematurity; SDZ standard deviation.
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outcomes between these groups, though there was small
sample size.
The rate of surfactant use and the need of intubation
were lower in the one-dose ACS and multiple-dose ACS
groups than that in the no-ACS group. Subsequently, we
found there were no significant differences in the rate of
surfactant use and the rate of intubation between one dose
and multiple doses of ACS. Ikegami and colleagues14
reported that one-dose antenatal betamethasone expo-
sure improved lung compliance and decreased lung edema
in a fetal lamb model. Due to the above results, the
condition of lung maturation was not significantly different
between one dose and multiple doses of ACS; it implied
that one-dose ACS still assisted lung maturation during the
fetal period.
Betamethasone and dexamethasone are the two most
extensively used medications for fetal maturation in
human. Betamethasone and dexamethasone both are dia-
stereoisomers and synthetic; the orientation of a methylTable 3 Effectiveness of multiple-dose antenatal corticosteroid
logistic regression adjusted for gestational age and birth body we
Odds ratio
Need for surfactant 1.078
Need for intubation 0.678
PDA 0.729
PDA with need of indomethacin/ligation 1.200
Intraventricular hemorrhage 1.881
Necrotizing enterocolitis 1.750
Chronic lung disease 0.404
Sepsis < 48 hr after birth 0.763
Retinopathy of prematurity 0.604
PDAZ patent ductus arteriosus.group on position C16 (b configuration for betamethasone,
and a configuration for dexamethasone) is the only struc-
tural difference between them. The pharmacokinetics of
these two drugs are similar due to there being such minimal
structural difference, and both of them cross the placenta
mainly in biologically active form.15 However, the results on
comparison of the efficiency between these two medica-
tions were inconsistent. The effect of these two drugs have
been shown to decrease the incidence of RDS, neonatal
mortality, PDA, NEC, and ROP. However, when the effect
was referred to reduce the incidence of IVH, dexametha-
sone was better than betamethasone.16 Nevertheless, the
clinical reports of Lee and others17 and Bar-Lev and
colleagues18 revealed there was no significant difference in
the rate of IVH between betamethasone and dexametha-
sone groups. Our study demonstrated outcomes similar to
those of Lee and Bar-Lev. Furthermore, the neurological
outcomes measured by the Bayley Scales of Infant Devel-
opment II showed no significant difference between these
two groups (data not shown).s compared with one-dose antenatal corticosteroids by using
ight.
95% confidence interval p value
0.339e3.554 0.899
0.253e1.773 0.431
0.298e1.763 0.484
0.452e3.271 0.761
0.604e6.329 0.286
0.315e13.436 0.538
0.136e1.140 0.092
0.282e2.059 0.591
0.195e1.827 0.372
Table 4 Neonatal outcomes of study population who were exposed to different types of antenatal corticosteroids.
Basic No-ACS
(nZ 174)
Betamethasone
group (nZ 8)
Dexamethasone
group (nZ 50)
p value* p valuey
Gestational age (wks, mean SD) 29.0 3.1 28.0 1.7 29.6 2.5 0.273 0.094
Birth weight (g, mean SD) 1147 262 949192 1231 192 0.006 0.001
Survival (n, %) 145 (83.33%) 8 (100.00%) 44 (88.00%) 0.344 0.301
Need for surfactant (n, %) 114 (66.28%) 5 (71.43%) 18 (36.73%) 0.001 0.081
Need for intubation (n, %) 129 (74.14%) 6 (75.00%) 27 (54.00%) 0.022 0.265
PDA (n, %) 98 (56.32%) 1 (12.5%) 30 (60.00%) 0.040 0.012
PDA with need of indomethacin/
ligation (n, %)
74 (44.31%) 1 (12.50%) 17 (34.00%) 0.214 0.222
IVH (n, %) 37 (22.02%) 0 (0.00%) 13 (26.53%) 0.247 0.097
IVH  Grade III (n, %) 11 (6.55%) 0 (0.00%) 7 (14.29%) 0.150 0.254
ROP any stage (n, %) 38 (30.65%) 1 (12.50%) 14 (36.84%) 0.475 0.245
ROPstage III (n, %) 17 (13.71%) 0 (0.00%) 2 (5.26%) 0.347 0.535
Sepsis < 48 hr after birth (n, %) 52 (29.89%) 1 (12.50%) 12 (24.00%) 0.440 0.469
Sepsis during hospitalization (n, %) 58 (33.33%) 1 (12.50%) 18 (38.00%) 0.426 0.189
Necrotizing enterocolitis (n, %) 8 (4.60%) 0 (0.00%) 5 (10.20%) 0.254 0.344
Chronic lung disease (N1, N2, %) 59, 151, 39.1% 2, 8, 25.00% 11,47,23.40% 0.122 0.922
*p value comparing with the no-ACS, betamethasone, and dexamethasone groups, significant pairs from Tukey’s pairwise comparison:
betamethasone vs. dexamethasone p value.
yp value comparing with the betamethasone and dexamethasone groups.
ACSZ antenatal corticosteroids; IVHZ intraventricular hemorrhage; PDAZ patent ductus arteriosus; ROPZ retinopathy of prematu-
rity; N1Z infants who used O2 > postconceptional age 36 wks; N2Z infants who survived > postconceptional age 36 wks, p value; SD:
standard deviation.
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and PDA has been noted.19 Prostaglandin E2(PGE2) is impor-
tant in closure of the ductus arteriosus after birth. During
normal fetal development, circulating cortisol concentra-
tions increase near the end of gestation, which was found to
decrease the sensitivity of the ductus to the vasodilating
effects of PGE2.
20 Consistent with this finding, ACS caused
a reduction in the incidence of PDA20 and increased the rate
of ductal closure.21 In our study, the rate of PDAwith need for
operation/indomethacinwas higher in the no-ACS group than
in other groups. This implied both betamethasone and
dexamethasone might decrease the incidence of RDS and
influence PGE2, and then decrease the symptomatic PDA.
There have been some concerns about ACS use,
including increased susceptibility of infection,22 and impact
on neurodevelopmental abnormalities.7 The rates of
neonatal infection, including early sepsis (< 48 hours after
birth) and all sepsis during hospitalization, and neurological
outcomes measured by the Bayley Scales of Infant Devel-
opment II were not significantly different between these
groups in this study.
In conclusion, ACS can decrease the incidence of intu-
bation and surfactant use. The neonatal outcomes were not
significant different between one-dose ACS and multiple-
dose ACS. To obtain more reliable and objective informa-
tion, further research including randomized control trials is
necessary.
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